# US 2012/0252861 A1 · Medical Compositions for Intravesical Treatment of Bladder Cancer

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2012/0252861 A1
- Document ID: US20120252861A1
- Status: Published application
- Kind: A1
- Application number: 13/493,911
- Filed: 2012-06-11
- Published: 2012-10-04
- Earliest claimed: 2001-11-01
- Assignees: Spectrum Pharmaceuticals, Inc.
- Inventors: Bastiaan Nuijen; Ernie Pfadenhauer; Jos H. Beijnen
- Web page: https://patentgrep.com/patent/US20120252861A1

## CPC

- A61K 9/19: lyophilised {, i.e. freeze-dried, solutions or dispersions (lyophilised products with subsequent particle size reduction A61K9/14; granules or pellets made by lyphilisation A61K9/1682; solid oral dosage forms made by lyophilisation A61K9/2095; lyophilisation additives A61K47/00)}
- A61K 9/0034: {Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants}
- A61K 31/404: Indoles, e.g. pindolol
- A61P 13/10: of the bladder
- A61P 35/00: Antineoplastic agents
- A61P 35/04: specific for metastasis
- A61K 9/127: Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

Anti-cancer coating compositions comprising 3-hydroxymethyl-5-aziridinyl-1-1-methyl-2-[1H-indole-4,7-dione]propenol (E09) are disclosed. More specifically, the coating compositions comprise EO9 and a formulation vehicle. The formulation vehicle improves the solubility and stability of EO9. Additionally, the coating compositions can include coating agents that provide better adhesion of the coating composition to the bladder wall during intravesical delivery of the coating composition.

## Claims

### Claim 1

A drug delivery system comprising EO9 and propylene glycol, wherein the drug delivery system is configured to administer the EO9 and the propylene glycol to the bladder via intravesical administration.

### Claim 2 (depends on 1)

The system of claim 1, further comprising sodium bicarbonate.

### Claim 3 (depends on 1)

The system of claim 1, further comprising disodium edetate.

### Claim 4 (depends on 1)

The system of claim 1, comprising about 0.5 mg to about 16 mg of EO9.

### Claim 5 (depends on 1)

The system of claim 1, further comprising water.

### Claim 6

A composition comprising about 0.5 mg to about 16 mg of EO9, propylene glycol, sodium bicarbonate, and EDTA.

### Claim 7 (depends on 6)

The composition of claim 6, further comprising water.
